{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CD45+antibodies", "query": { "intervention": "CD45 antibodies" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CD45+antibodies&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T13:18:31.404Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01921387", "title": "Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Hodgkin Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory T-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2013-10-09", "completion_date": "2020-07-26", "has_results": true, "last_update_posted_date": "2020-08-04", "last_synced_at": "2026-09-10T13:18:31.404Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01921387" }, { "nct_id": "NCT00860171", "title": "Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Hodgkin Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma", "Refractory T-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Iodine I 131 Monoclonal Antibody BC8", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2009-02", "completion_date": "2020-03-21", "has_results": true, "last_update_posted_date": "2020-04-03", "last_synced_at": "2026-09-10T13:18:31.404Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00860171" }, { "nct_id": "NCT00586274", "title": "Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "FANCONI ANEMIA" ], "interventions": [ { "name": "CD34 selected haploidentical PBSCT", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "T cell infusion", "type": "BIOLOGICAL" }, { "name": "Campath 1h", "type": "BIOLOGICAL" }, { "name": "anti-CD45", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "64 Years", "sex": "ALL", "summary": "Up to 64 Years" }, "enrollment_count": 1, "start_date": "2002-03", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2014-03-04", "last_synced_at": "2026-09-10T13:18:31.404Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00586274" }, { "nct_id": "NCT00590460", "title": "Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fanconi Anemia", "Severe Aplastic Anemia" ], "interventions": [ { "name": "CAMPATH-1H", "type": "BIOLOGICAL" }, { "name": "Anti-CD45", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Stem cell infusion", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5, "start_date": "2001-07", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2018-05-24", "last_synced_at": "2026-09-10T13:18:31.404Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00590460" }, { "nct_id": "NCT03597594", "title": "Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Severe Combined Immunodeficiency" ], "interventions": [ { "name": "Anti-thymocyte globulin (rabbit)", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "CliniMACS", "type": "DEVICE" }, { "name": "Donor Lymphocyte Infusion", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DEVICE", "OTHER" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": null, "sex": "ALL", "summary": "2 Months and older" }, "enrollment_count": 4, "start_date": "2021-09-02", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-09-10T13:18:31.404Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03597594" }, { "nct_id": "NCT00003868", "title": "Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "iodine I 131 monoclonal antibody BC8", "type": "RADIATION" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "2 Years to 55 Years" }, "enrollment_count": 40, "start_date": "1999-02", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2010-08-24", "last_synced_at": "2026-09-10T13:18:31.404Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003868" }, { "nct_id": "NCT01300572", "title": "Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myelomonocytic Leukemia", "Previously Treated Myelodysplastic Syndrome", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "Allogeneic Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Indium In 111 Anti-CD45 Monoclonal Antibody BC8", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2012-01", "completion_date": "2019-11-22", "has_results": true, "last_update_posted_date": "2019-12-10", "last_synced_at": "2026-09-10T13:18:31.404Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01300572" }, { "nct_id": "NCT06679582", "title": "Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Luveltamab tazevibulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sutro Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "12 Years", "sex": "ALL", "summary": "1 Day to 12 Years" }, "enrollment_count": 24, "start_date": "2024-12-04", "completion_date": "2025-06-01", "has_results": false, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-09-10T13:18:31.404Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06679582" }, { "nct_id": "NCT00579137", "title": "Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Severe Combined Immunodeficiency Disease", "Severe Primary Immunodeficiency Disorder", "Undefined T Cell Deficiency Disorder", "Wiskott-Aldrick Syndrome" ], "interventions": [ { "name": "Campath -1H", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Anti-CD45", "type": "BIOLOGICAL" }, { "name": "Stem cell infusion", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 3, "start_date": "2007-10", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-09-10T13:18:31.404Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00579137" }, { "nct_id": "NCT00057005", "title": "Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "LEUKEMIA" ], "interventions": [ { "name": "CAMPATH-1H", "type": "DRUG" }, { "name": "Anti-CD45", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "45 Years", "sex": "ALL", "summary": "Up to 45 Years" }, "enrollment_count": 6, "start_date": "2003-02", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-09-10T13:18:31.404Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00057005" } ] }